Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Swaminathan Murugappan"'
Autor:
Houston Holmes, Ian W. Flinn, Patrick M. Reagan, Max S. Topp, John M. Timmerman, Weimin Peng, Michael Wang, Roch Houot, John M. Pagel, Amer Beitinjaneh, David B. Miklos, Peter A. McSweeney, Swaminathan Murugappan, Marie José Kersten, Andre Goy, Frederick L. Locke, Lianqing Zheng, Samantha Jaglowski, Javier Munoz, Noel Milpied, John M. Rossi, Caron A. Jacobson, Henry C.H. Fung, Ioana Kloos, Brian T. Hill
Publikováno v:
Blood. 136:20-22
Background: KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is currently being evaluated in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who received 1 - 5 prior therapies (including a Bruton tyr
Autor:
Ian W. Flinn, David B. Miklos, John M. Timmerman, Ioana Kloos, Patrick M. Reagan, Roch Houot, Andre Goy, Marie José Kersten, Brian T. Hill, Lianqing Zheng, Houston Holmes, Noel Milpied, Henry C. Fung, Michael L. Wang, Frederick L. Locke, Peter A. McSweeney, Samantha Jaglowski, Amer Beitinjaneh, Max S. Topp, Caron A. Jacobson, John M. Rossi, John M. Pagel, Javier Munoz, Weimin Peng, Swaminathan Murugappan
Publikováno v:
Transplantation and Cellular Therapy. 27:S342
Autor:
John C. Byrd, William G. Wierda, John M. Pagel, Swaminathan Murugappan, Ian W. Flinn, Yan Zheng, Krista Goodman, Michael Marris, Jennifer R. Brown, Steven Coutre, Francesca Milletti, Lovely Goyal
Publikováno v:
Journal of Clinical Oncology. 37:TPS7566-TPS7566
TPS7566 Background: Despite treatment advances, CLL is largely incurable. First-line targeted therapy with ibrutinib mostly produces durable remissions, but high-risk disease or many prior therapies increases relapse risk (Ghia P, et al. Haematologic
Autor:
Satya P. Kunapuli, Ramya Chari, Archana Sanjay, James L. Daniel, Soochong Kim, Swaminathan Murugappan
Publikováno v:
Blood. 114:3056-3063
Protein kinase C-delta (PKC-delta) is expressed in platelets and activated downstream of protease-activated receptors (PARs) and glycoprotein VI (GPVI) receptors. We have previously shown that PKC-delta positively regulates PAR-mediated dense granule
Autor:
Béla Nagy, Keiko Nakayama, Ramya Chari, Kamala Bhavaraju, Swaminathan Murugappan, Todd M. Getz, Yamini Saraswathy Bynagari, Satya P. Kunapuli, Yingying Mao
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 29:699-705
Objective— Protein Kinase C delta (PKCδ) is expressed in platelets and activated downstream of protease-activated receptors (PAR)s and glycoprotein VI (GPVI) receptors. The purpose of this study was to investigate the role of PKCδ in platelets. M
Publikováno v:
Biochemical Journal. 417:113-120
Phosphorylation of activation loop threonine (Thr(505)) and regulatory domain tyrosine (Tyr(311)) residues are key regulators of PKC (protein kinase C) delta function in platelets. In the present study, we show that G(q) and G(12/13) pathways regulat
Autor:
Haripriya Shankar, Satya P. Kunapuli, Jianguo Jin, Surya Bhamidipati, Swaminathan Murugappan, Robert T. Dorsam
Publikováno v:
Blood. 106:550-557
Thrombin has been known to cause tyrosine phosphorylation of protein kinase C δ (PKCδ) in platelets, but the molecular mechanisms and function of this tyrosine phosphorylation is not known. In this study, we investigated the signaling pathways used
Autor:
Satya P. Kunapuli, Soochong Kim, Swaminathan Murugappan, Robert T. Dorsam, Jianguo Jin, Swathi Rachoor, Haripriya Shankar
Publikováno v:
Blood. 105:2749-2756
G(12/13) or G(q) signaling pathways activate platelet GPIIb/IIIa when combined with G(i) signaling. We tested whether combined G(i) and G(z) pathways also cause GPIIb/IIIa activation and compared the signaling requirements of these events. Platelet a
Publikováno v:
Seminars in Thrombosis and Hemostasis. 30:411-418
Adenosine diphosphate (ADP) and thromboxane A (2) (TXA (2)) are important physiological activators of platelets and exert their effects by acting on cell surface receptors. Platelet nucleotide receptors can be distinguished as three separate subtypes
Publikováno v:
Journal of Clinical Oncology. 35:9561-9561
9561 Background: To assess melanoma specific health-related quality of life (HRQoL) and health states in patients with earlier stage metastatic (IIIb/c-IVM1a) versus late stage metastatic (IVM1b/c) melanoma. Methods: Data were collected from the Adel